TY - JOUR
T1 - Combination immunotherapy for cancer
T2 - Synergistic antitumor interactions of interleukin-2, alfa interferon, and tumor-infiltrating lymphocytes
AU - Rosenberg, Steven A.
AU - Schwarz, Susan L.
AU - Spiess, Paul J.
PY - 1988/11/2
Y1 - 1988/11/2
N2 - Attempts have been made to design optimal strategies for the immunotherapy of established tumors. In micebearing pulmonary metastases from sarcomas, a substantial therapeutic synergy was seen when bothinterleukin-2(IL-2) and alfa interferon(α-IFN) were administered compared with the effect of either agentgiven alone. This synergy was dependent on Lyt-2+T cells, since therapeutic effects were abrogated in Lyt-2 depleted mice. The αIFN and IL-2 combination was also synergistic with tumor-infiltrating lymphocytes inmediating the reduction of established lung metastases. These experiments demonstrate that combination immunotherapy can result in substantial reduction of established metastatic deposits and provide a rationale for the application of this treatment to patients with advanced cancer. [J National Cancer Inst 1988;80:1393-1397]
AB - Attempts have been made to design optimal strategies for the immunotherapy of established tumors. In micebearing pulmonary metastases from sarcomas, a substantial therapeutic synergy was seen when bothinterleukin-2(IL-2) and alfa interferon(α-IFN) were administered compared with the effect of either agentgiven alone. This synergy was dependent on Lyt-2+T cells, since therapeutic effects were abrogated in Lyt-2 depleted mice. The αIFN and IL-2 combination was also synergistic with tumor-infiltrating lymphocytes inmediating the reduction of established lung metastases. These experiments demonstrate that combination immunotherapy can result in substantial reduction of established metastatic deposits and provide a rationale for the application of this treatment to patients with advanced cancer. [J National Cancer Inst 1988;80:1393-1397]
UR - http://www.scopus.com/inward/record.url?scp=0023757460&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023757460&partnerID=8YFLogxK
U2 - 10.1093/jnci/80.17.1393
DO - 10.1093/jnci/80.17.1393
M3 - Article
C2 - 3262772
AN - SCOPUS:0023757460
SN - 0027-8874
VL - 80
SP - 1393
EP - 1397
JO - Journal of the National Cancer Institute
JF - Journal of the National Cancer Institute
IS - 17
ER -